volume 36, issue 2, P245-250 2012
DOI: 10.2337/dc12-0872
View full text
|
Sign up to set email alerts
|
Share

Abstract: OBJECTIVEAssessment of the efficacy and safety of TAK-875 (a novel GPR40 agonist) in Japanese patients with type 2 diabetes inadequately controlled by diet/exercise.RESEARCH DESIGN AND METHODSThis was a phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week dose-ranging evaluation of TAK-875 (6.25–200 mg once daily) with the primary end point of change in A1C at week 12. A nonblinded group received 1 mg glimepiride once daily as an active control.RESULTSA total of 396 pati…

Expand abstract